Back
 

View:
Mini 
BasicThis view is available after user registration.
 
ShortThis view is available when you buy a license.
 
StandardThis view is available when you buy a license.
 
CompleteThis view is available when you buy a license.
 

Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan consolidation, follicular lymphoma grade I-IIIa

Protocol-ID: 305 V1.0 (Mini), RITU250/90YITT cons., foll. Lymphoma °I-IIIa

Indication(s)

  • NHL, B-Cell Type, Follicular Grade I-IIIa; ICD-10 C82.9
  • NHL, B-Cell Type, Indolent
ST
Radiotherapy: 90Yttrium Ibritumomab-Tiuxetan
On day 1 after rituximab, 185 MBq 111 indium ibritumomab tiuxetan On day 8 after rituximab, 14.8 MBq/kg 90 YIT to a maximum dose of 1148 MBq
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 29.12.2014